480 related articles for article (PubMed ID: 24389101)
1. Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia.
Cao F; Townsend EC; Karatas H; Xu J; Li L; Lee S; Liu L; Chen Y; Ouillette P; Zhu J; Hess JL; Atadja P; Lei M; Qin ZS; Malek S; Wang S; Dou Y
Mol Cell; 2014 Jan; 53(2):247-61. PubMed ID: 24389101
[TBL] [Abstract][Full Text] [Related]
2. High-affinity small molecular blockers of mixed lineage leukemia 1 (MLL1)-WDR5 interaction inhibit MLL1 complex H3K4 methyltransferase activity.
Li DD; Chen WL; Wang ZH; Xie YY; Xu XL; Jiang ZY; Zhang XJ; You QD; Guo XK
Eur J Med Chem; 2016 Nov; 124():480-489. PubMed ID: 27598236
[TBL] [Abstract][Full Text] [Related]
3. Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.
Chen WL; Li DD; Chen X; Wang YZ; Xu JJ; Jiang ZY; You QD; Guo XK
Eur J Med Chem; 2020 Feb; 188():112027. PubMed ID: 31923859
[TBL] [Abstract][Full Text] [Related]
4. Piribedil disrupts the MLL1-WDR5 interaction and sensitizes MLL-rearranged acute myeloid leukemia (AML) to doxorubicin-induced apoptosis.
Zhang X; Zheng X; Yang H; Yan J; Fu X; Wei R; Xu X; Zhang Z; Yu A; Zhou K; Ding J; Geng M; Huang X
Cancer Lett; 2018 Sep; 431():150-160. PubMed ID: 29857126
[TBL] [Abstract][Full Text] [Related]
5. On the mechanism of multiple lysine methylation by the human mixed lineage leukemia protein-1 (MLL1) core complex.
Patel A; Dharmarajan V; Vought VE; Cosgrove MS
J Biol Chem; 2009 Sep; 284(36):24242-56. PubMed ID: 19556245
[TBL] [Abstract][Full Text] [Related]
6. Automethylation activities within the mixed lineage leukemia-1 (MLL1) core complex reveal evidence supporting a "two-active site" model for multiple histone H3 lysine 4 methylation.
Patel A; Vought VE; Swatkoski S; Viggiano S; Howard B; Dharmarajan V; Monteith KE; Kupakuwana G; Namitz KE; Shinsky SA; Cotter RJ; Cosgrove MS
J Biol Chem; 2014 Jan; 289(2):868-84. PubMed ID: 24235145
[TBL] [Abstract][Full Text] [Related]
7. Structural basis for WDR5 interaction (Win) motif recognition in human SET1 family histone methyltransferases.
Dharmarajan V; Lee JH; Patel A; Skalnik DG; Cosgrove MS
J Biol Chem; 2012 Aug; 287(33):27275-89. PubMed ID: 22665483
[TBL] [Abstract][Full Text] [Related]
8. Targeted Disruption of the Interaction between WD-40 Repeat Protein 5 (WDR5) and Mixed Lineage Leukemia (MLL)/SET1 Family Proteins Specifically Inhibits MLL1 and SETd1A Methyltransferase Complexes.
Alicea-Velázquez NL; Shinsky SA; Loh DM; Lee JH; Skalnik DG; Cosgrove MS
J Biol Chem; 2016 Oct; 291(43):22357-22372. PubMed ID: 27563068
[TBL] [Abstract][Full Text] [Related]
9. Structure-based design of ester compounds to inhibit MLL complex catalytic activity by targeting mixed lineage leukemia 1 (MLL1)-WDR5 interaction.
Li DD; Wang ZH; Chen WL; Xie YY; You QD; Guo XK
Bioorg Med Chem; 2016 Nov; 24(22):6109-6118. PubMed ID: 27720555
[TBL] [Abstract][Full Text] [Related]
10. Histone methyltransferase MLL1 regulates MDR1 transcription and chemoresistance.
Huo H; Magro PG; Pietsch EC; Patel BB; Scotto KW
Cancer Res; 2010 Nov; 70(21):8726-35. PubMed ID: 20861184
[TBL] [Abstract][Full Text] [Related]
11. The Development of Inhibitors Targeting the Mixed Lineage Leukemia 1 (MLL1)-WD Repeat Domain 5 Protein (WDR5) Protein- Protein Interaction.
Ye X; Chen G; Jin J; Zhang B; Wang Y; Cai Z; Ye F
Curr Med Chem; 2020; 27(33):5530-5542. PubMed ID: 31132972
[TBL] [Abstract][Full Text] [Related]
12. Structural basis of nucleosome recognition and modification by MLL methyltransferases.
Xue H; Yao T; Cao M; Zhu G; Li Y; Yuan G; Chen Y; Lei M; Huang J
Nature; 2019 Sep; 573(7774):445-449. PubMed ID: 31485071
[TBL] [Abstract][Full Text] [Related]
13. Regulation of MLL1 H3K4 methyltransferase activity by its core components.
Dou Y; Milne TA; Ruthenburg AJ; Lee S; Lee JW; Verdine GL; Allis CD; Roeder RG
Nat Struct Mol Biol; 2006 Aug; 13(8):713-9. PubMed ID: 16878130
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the binding of mixed lineage leukemia 1 (MLL1) and histone 3 peptides to WD repeat domain 5 (WDR5) for the design of inhibitors of the MLL1-WDR5 interaction.
Karatas H; Townsend EC; Bernard D; Dou Y; Wang S
J Med Chem; 2010 Jul; 53(14):5179-85. PubMed ID: 20575550
[TBL] [Abstract][Full Text] [Related]
15. High-affinity, small-molecule peptidomimetic inhibitors of MLL1/WDR5 protein-protein interaction.
Karatas H; Townsend EC; Cao F; Chen Y; Bernard D; Liu L; Lei M; Dou Y; Wang S
J Am Chem Soc; 2013 Jan; 135(2):669-82. PubMed ID: 23210835
[TBL] [Abstract][Full Text] [Related]
16. Discovery of
Chen W; Chen X; Li D; Zhou J; Jiang Z; You Q; Guo X
J Med Chem; 2021 Jun; 64(12):8221-8245. PubMed ID: 34105966
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the H3K4 methyltransferase MLL1/WDR5 complex attenuates renal senescence in ischemia reperfusion mice by reduction of p16
Shimoda H; Doi S; Nakashima A; Sasaki K; Doi T; Masaki T
Kidney Int; 2019 Nov; 96(5):1162-1175. PubMed ID: 31570196
[TBL] [Abstract][Full Text] [Related]
18. Hematopoietic transformation in the absence of MLL1/KMT2A: distinctions in target gene reactivation.
Chen Y; Ernst P
Cell Cycle; 2019 Jul; 18(14):1525-1531. PubMed ID: 31161857
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a potent MLL1 and WDR5 protein-protein interaction inhibitor with in vivo antitumor activity.
Chen W; Chen X; Li D; Wang X; Long G; Jiang Z; You Q; Guo X
Eur J Med Chem; 2021 Nov; 223():113677. PubMed ID: 34225179
[TBL] [Abstract][Full Text] [Related]
20. Targeting human SET1/MLL family of proteins.
Vedadi M; Blazer L; Eram MS; Barsyte-Lovejoy D; Arrowsmith CH; Hajian T
Protein Sci; 2017 Apr; 26(4):662-676. PubMed ID: 28160335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
